Because CD200 does not have a signaling domain it appears that anti-CD200 Abs do not directly affect targeted tumor cells, and Kretz-Rommel et al. [30] demonstrated that the anti-CD200 mAbs, as expected, did not inhibit tumor cell proliferation or directly induce cell death [31]. The gene discussed is CD200; the disease is neoplasm.